TScan Therapeutics Inc.
TCRX
We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hem…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$7M
▲ +266.7% YoY
Net Income (TTM)
-$118M
▼ -1.8% YoY
Op. Margin
-1695.15%
▲ +3472.3pp YoY
ROIC
-47.24%
▼ -2.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$118M
▼ -21.9% YoY
Op. Cash Flow (TTM)
-$116M
▼ -22.1% YoY
Net Debt
-$9M
Net Cash Position
Cash & Equiv.
$100M
5Y CAGR: +56.9%
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with TCRX
TScan Therapeutics (TCRX) in four numbers
Questions about TScan Therapeutics
Is TScan Therapeutics (TCRX) overvalued?
At $0.19, TScan Therapeutics' price is 63% below the $0.50 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is TScan Therapeutics' fair value?
Intrinsiqq's calculator puts TScan Therapeutics' fair value at $0.50 a share. It grows revenue per share 0% a year for 5 years, applies an exit P/S of 14.8, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.38. Every input can be changed on the Intrinsic Value tab.
Is TScan Therapeutics a high-quality business?
TScan Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$9M, and its weakest is return on capital at -47.2%. The Quality tab shows every check against its target.
Does TScan Therapeutics (TCRX) pay a dividend?
No. TScan Therapeutics (TCRX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 12 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in TCRX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing TCRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.